RIPK1-IN-19
Based on 1 Customer Validation
RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases.
For research use only. We do not sell to patients.
- Purity : 98.87%
- CAS No.: 2763831-43-0
- Formula: C28H25FN6O2
- Molecular Weight:496.54
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
RIPK1 15 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | EC50 |
0.032 nM
Compound: 10b
|
Protection against TSZ-induced necroptosis in human HT-29 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
Protection against TSZ-induced necroptosis in human HT-29 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
|
[PMID: 38159286] |
| J774.A1 | EC50 |
75.3 pM
Compound: 10b
|
Protection against TSZ-induced necroptosis in mouse J774.A1 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
Protection against TSZ-induced necroptosis in mouse J774.A1 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
|
[PMID: 38159286] |
| L929 | EC50 |
10.2 pM
Compound: 10b
|
Protection against TSZ-induced necroptosis in mouse L929 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
Protection against TSZ-induced necroptosis in mouse L929 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
|
[PMID: 38159286] |
| U-937 | EC50 |
47.8 pM
Compound: 10b
|
Protection against TSZ-induced necroptosis in human U-937 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
Protection against TSZ-induced necroptosis in human U-937 cells preincubated with compound followed by TNA-alpha,Smac mimetic and Z-VAD-FMK addition and measured after 24 hrs by CCK-8 assay
|
[PMID: 38159286] |
In Vitro
RIPK1-IN-19 (compound 10b) effectively protects U937, J774A.1, and L929 cells from necroptosis with EC50 values of 47.8, 75.3, and 10.2 pM, respectively[1].
RIPK1-IN-19 (0.03-300 nM) inhibits the phosphorylation of RIPK1 and its downstream signaling proteins RIPK3 and MLKL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | Tmax | AUC0-t | F |
|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | p.o. | 5.21 h | 401.86 ng/mL | 0.5 h | 2353.02 ng·h/mL | 15.31 % |
In Vivo
The topical administration of RIPK1-IN-19 (10%) ameliorates the psoriasis-like skin symptoms by reducing skin scaling and thickening in Imiquimod-induced psoriasis model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (aged 6-8 weeks, ~20 g)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; for around 15 min and then challenged with mouse TNF-α (450 μg/kg)
-
Result:Dramatically increased the survival rate of TNFα-treated mice.
Strongly reduced TNFα-induced temperature loss in mice.
Significantly reduced the contents of proinflammatory cytokines including IL-1β and IL-6.
Chemical Information
-
CAS No. 2763831-43-0
-
Appearance Solid
-
Molecular Weight 496.54
-
Formula C28H25FN6O2
-
Color Light brown to brown
-
SMILES
C[C@@H](C1=CC=CC(F)=C1)NC(C2=CN(C3=C2C=C(C=C3)C4=CC5=NC(NC(C6CC6)=O)=NN5C=C4)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)